Location History:
- Milan, IT (1993)
- Turbigo, IT (1991 - 1994)
Company Filing History:
1 out of 480 
1 out of 43 
1 out of 22 Years Active: 1991-1994
Title: Paolo Golini: Innovator in Enzymatic Processes
Introduction
Paolo Golini is a notable inventor based in Turbigo, Italy, recognized for his contributions to the field of enzymatic processes. With a total of three patents to his name, Golini has made significant advancements in the preparation and separation of optical isomers, which are crucial in the synthesis of various chiral drugs.
Latest Patents
Golini's latest patents include a process for preparing (R) and (S)-1,2-isopropylideneglycerol. This innovative process involves partially stereoselective enzymatic hydrolysis of 1,2-isopropylideneglycerol benzoyl ester, catalyzed by a free or immobilized lipase. The hydrolysis is conducted in the presence of a cosolvent, followed by crystallization, which allows for the selective obtaining of crystals in racemic form and pure enantiomers. The compound is widely used as an intermediate in the synthesis of chiral drugs, including (R)-(-)-carnitine and (S)-beta-blockers. Another significant patent involves an enzymatic process for separating the optical isomers of racemic 1,2-diols, showcasing Golini's expertise in this specialized area.
Career Highlights
Throughout his career, Golini has worked with prominent organizations, including Montedison S.p.a. and the Ministero dell'Università e della Ricerca Scientifica e Tecnologica. His work in these institutions has allowed him to develop and refine his innovative processes, contributing to advancements in the field of chemistry and pharmaceuticals.
Collaborations
Golini has collaborated with notable colleagues, including Daniele Bianchi and Pietro Cesti. These partnerships have fostered a collaborative environment that has enhanced the development of his patented processes.
Conclusion
Paolo Golini's contributions to the field of enzymatic processes and his innovative patents have made a significant impact on the synthesis of chiral drugs. His work continues to influence the pharmaceutical industry, showcasing the importance of innovation in scientific research.